GSK Boosts Annual Profit and Sales Forecast Amid Strong Cancer and HIV Drug Growth

British pharmaceutical giant GSK has raised its annual profit and sales forecasts, attributing this success to strong performance in its cancer and HIV drug portfolio. The company now anticipates an 11% to 13% rise in profits and a 7% to 9% increase in sales for the year.

On Wednesday, GSK announced an upward revision of its annual profit and sales forecast, thanks to robust growth in its cancer and HIV drug portfolio.

The British pharmaceutical giant now predicts a profit increase of between 11% and 13% for the year, alongside a sales growth ranging from 7% to 9%.

This updated forecast underscores the company's strong performance in critical therapeutic areas.